The differential expression of the desired gene product in the target tissue is central for gene therapy. One approach is to use a tissue-specific promoter to drive therapeutic gene expression. UroplakinII (UPII) is a urothelium-specific membrane protein. To investigate the feasibility of targeting gene therapy for bladder cancer, a DNA fragment of 2542-bp upstream of the UPII gene was amplified by PCR and linked to a promoterless firefly luciferase reporter gene. The transient transfection showed that the DNA fragment resulted in preferential expression in bladder carcinoma cells, with negligible expression in nonurothelium cells. Furthermore, the DNA segment located between À2545 and À1608 decided the tissue-specificity of the UPII promoter, the segment located between À328 and À4 being the core promoter of UPII. We generated two recombinant adenoviruses under the control of the UPII promoter: Ad-hUPII-GFP, carrying green fluorescence protein (GFP), and Ad-hUPII-TNF, carrying the tumor necrosis factor alpha (TNFa). ELISA revealed that the secretion of TNFa by Ad-hUPII-TNF-infected bladder cancer cells was significantly higher than Ad-hUPII-TNF-infected nonurothelium cells. The conditioned medium from Ad-hUPII-TNF-infected bladder cancer cells apparently inhibited the proliferation of L929 cells, a TNFa-sensitive cell line, comparing to Ad-hUPII-TNF-infected nonurothelium cells. Intravesical inoculation with Ad-hUPII-TNF inhibited tumor growth in the orthotopic human bladder cancer model. The sustained high level of TNFa in urine was identified with ELISA. Taken together, these data suggest that most of the cis elements that confer the bladder-specificity and differentiationdependent expression of the human UPII gene reside in the 2542-bp sequence, and TNFa driven by the human UPII (hUPII) promoter is effective in the specific inhibition of bladder cancer growth both in vivo and in vitro. These results may yield a new therapeutic approach for bladder cancer and provide information on the molecular regulation of urothelial growth, differentiation, and disease.
T ransitional cell carcinoma of the bladder is the most common malignancy of all of the urinary cancers. 1 Approximately 50,000 new cases are diagnosed, and 11,000 patients die from the disease every year. 2 The administration of intravesical chemotherapy or immunotherapy prolongs the progression-free interval after initial transurethral resection, 3, 4 but the recurrent rate is about 20%. As many as 30% of these recurrent tumors have a high-grade invasive property. 5 Gene therapy for cancer has become a more realistic approach than chemo-or immunotherapy because of the rapid advances in molecular biology techniques. [6] [7] [8] The differential expression of the desired gene in the target tissue is essential for gene therapy. [9] [10] [11] [12] One of the approaches is to use a tissue-specific promoter to drive therapeutic gene expression. Since the tissuespecific promoter has activity in special cells, using this point for targeting gene therapy instead of a systemic approach can effectively prevent systemic toxicity. 13 For example, prostate-specific antigen promoter was used for prostate cancer treatment. 14 A limited, efficient, tissue-specific promoter has yet to be found in the urothelium.
A group of bladder tissue-specific proteins, uroplakins, including uroplakinIa (UPIa), uroplakinIb (UPIb), uroplakinII (UPII), and uroplakinIII (UPIII), have been characterized. 15 The expression of uroplakins was found to be limited to bladder-derived cells. 16, 17 Therefore, the promoters that direct the expression of the uroplakins may be useful in constructing tissue-specific vectors for bladder cancer gene therapy.
In 1995, a mouse UPII promoter was characterized by Lin et al. 18 This promoter can drive a bacterial lac Z gene expression in the suprabasal cell layers of the mouse urothelium but not in other tissues.
In this study, we described the identification of a human urothelium-specific promoter and construction of a bladder-specific recombinant adenovirus. A growthinhibition effect was observed in a bladder tumor cell line infected with the recombinant adenovirus and an orthotopic human bladder tumor model.
Materials and methods

Cell lines and semiquantitation RT-PCR
The cell lines for bladder cancer (BIU-87 and EJ), renal carcinoma (GRC-1), vascular endothelium (EC), lung cancer (A549), and skin fibroblast (Hs27) were derived in our laboratory. They were all maintained in RPMI-1640 with 10% fetal bovine serum (FBS) (Hyclone Laboratories, Logan, OR) at 371C, 5% CO 2 .
The cells were lysed with 1.0 ml Trizol (Promega Corp., Madison, WI); the RNA was removed by chloroform extraction and recovered by isopropanol precipitation. Equal amounts of RNA (3 mg, as determined by spectrophotometry) from each sample were reverse-transcripted (RT) using an AMV reverse transcriptase kit (Promega Corp., Madison, WI). One-twentieth of the resultant cDNA was used for semiquantitative polymerase chain reaction (PCR) amplification, as described previously. 16 b-Actin served as an internal control to determine the RNA quality of the samples in the process of RT-PCR.
Cloning and subcloning of the UPII promoter
Human genome was isolated from human peripheral blood as a template. Four pairs of oligonucleotide primers (see Table 1 ) were designed. To clone the hUPII promoter, PCR was performed using 100 ng of genome DNA, 10 ng of each of the primers, 100 mM of each deoxynucleotide triphosphates, PCR reaction buffer, and 1.5 U of Pfx polymerase. The reaction was initiated at 951C for 2 minutes, 551C for 30 seconds, and 721C for 5 minutes. After 30 cycles, continued on 951C for 30 seconds, 551C for 30 seconds and 721C for 5 minutes. The reaction was ended with a final cycle of 951C, 551C for 30 seconds, respectively, and 721C for 10 minutes.
The resulting PCR product was designated as hUPII. After the digestion of HindIII, XhoI, and ApaI, the fragments were generated and designated as hUPII-1 DNA (from À1608 to À4 bp), hUPII-2 DNA (from À1034 to À4 bp), and hUPII-3 DNA (from À2545 to À1672 bp), respectively. Another two fragments generated by PCR approach were designated as UPII-4 (from À2545 to À328 bp) and UPII-5 (from À328 to À4 bp) (Fig 1) .
The hUPII was inserted into the pEGFP-1, an enhanced green fluorescence protein (GFP) reporter vector (Clontech, Palo Alto, CA). The hUPII, hUPII-1, hUPII-2, hUPII-3, hUPII-4, and hUPII-5 were subcloned into a pGL3-basic vector, a luciferase reporter vector (Promega Corp., Madison, WI). The plasmid pEGFP-N1 (Clontech, Palo Alto, CA) containing the cytomegalovirus (CMV) promoter was used as a positive control to monitor transfection and expression efficiency. The plasimid pEGFP-1 (Clontech, Palo Alto, CA) with no promoter was used as a negative control to determine levels of nonspecific transcription. The construct with the CMV-driven b-galactosidase was used as an internal control to normalize the levels of luciferase. The recombinant plasmid was purified and the plasmid concentration was determined by spectrophotometry.
Transient transfection and reporter detecting assay
Various GFP recombinant plasmids were transiently transfected into BIU-87, GRC-1, and EC cell using Lipofectamine 2000 (Life Technologies, Inc.). Briefly, 2 Â 10 5 cells/well were seeded into a 24-well plate and grown overnight until E70% confluent. After washing twice with 500 ml RPMI-1640 medium, the cells were covered by 1 mg DNA and 2 ml Lipofectamine 2000 mixture in 50 ml RPMI-1640 medium. After 6-hour incubation at 371C, 600 ml of RPMI-1640 with 20% FBS was added into plates and incubated at 371C until 24 hours later GFP activity of the cells was detected by confocal microscope. The percentage of GFP-positive cells was also determined by flow cytometry in duplicated experiment after the cells were trypsinized from plates and washed twice with phosphate buffer saline (PBS).
Luciferase recombinant plasmid DNA (0.8 mg) and bgalactosidase plasmid (0.2 mg) were cotransfected into BIU-87, EJ, A549, Hs27, GRC-1 and EC cell lines with Lipofectamine 2000 as described above. After 24 hours of cotransfection, 50 ml of reporter lysis buffer (Promega Corp., Madison, WI) was added to cover the cells and a freeze-thaw step was performed to ensure complete lysis. A volume of 20 ml of lysate was applied to measure bgalactosidase levels by ONPG methods. Luciferase values were determined by a luminometer (microplate) measuring the light emission for 1.2 seconds, after another aliquot of 20 ml cell lysate was mixed with 100 ml luciferase assay reagent.
Virus construction
pAdeasy was purchased from Stratagene Inc. Two replication-deficient recombinant adenoviruses were generated as described previously. 19 A 2542-bp DNA fragment from the hUPII 5 0 -flanking region and the tumor necrosis factor afpha (TNFa) gene were inserted into a pShuttle vector to create pShuttle-hUPII-TNF. The 2542-bp DNA fragment and GFP gene (pEGFP-1) were inserted into the pShuttle vector to create pShuttlehUPII-GFP.
pShuttle-hUPII-TNF and pShuttle-hUPII-GFP were cotransfected with pAdeasy-1 (think about the consistency with the above) by electroporation in electrocompetent E. coli BJ5183 cells. Positive plasmid was transformed into DH10B cells for large-scale amplification. Two positive plasmids were transfected into 293 cells by Lipofectamine 2000. After 7 days, the cells were lysed by three freeze-thaw cycles. A total of 1 ml of viral lysate was used to infect 293 cells once more. After 3 days, the culture medium of 293 cells showed the complete cytopathic effect. Viruses were harvested as described above. This process was repeated three times. After purification and a two-step CsCl 2 gradient ultracentrifugal concentration of the viral lysate, two adenoviruses (Ad-hUPII-TNF and Ad-hUPII-GFP) were generated. The viral titers were determined by plaque assay in 293 cells. Viral construction of Ad-hUPII-TNF was confirmed by PCR with primers (see Table 1 ) specific to the TNFa gene.
Adenoviral transduction in vitro
The infection of the BIU-87 and A549 cell lines using AdhUPII-TNF and Ad-hUPII-GFP was performed by adding the viral solutions in various multiplicities of infection (MOIs) to cell monolayers, followed by incubation at 371C for 2 hours. After 2 h of exposure to virus, fresh medium (containing 2% FBS) was added to the cells. The concentrations of TNFa in the medium, in which the cells were treated by various MOIs and durations, were determined by ELISA. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed to determine cell viability.
Orthotopic human bladder tumor model and intravesical instillation of adenovirus
Athymic BALB/c nude mice (nu/nu), 6 weeks old, were purchased from Peking University. Mice were anesthetized with intraperitoneal pentobarbital (50 mg/kg). AE1-cm skin incision was made transversely in the abdomen, just above the pubis. The anterior abdominal wall muscles were incised and the bladder was exteriorized. Urine was evacuated by aspiration. The bladder was washed twice with PBS. The external urethral orifice was ligated to prevent leakage. A measure of 50-ml 10 6 BIU-87 cells/mouse in serum-free RPMI-1640 medium was injected into the wall of the bladder with a 27-gauge needle; meanwhile, either 1 Â 10 8 PFU of Ad-hUPII-TNF or Ad-hUPII-GFP in 0.5 ml of PBS was injected into the lumen of the bladder. Ligatures were removed 1 hour later. At 48 hours after tumor implantation, three mice injected with Ad-hUPII-TNF and three with Ad-hUPII-GFP were killed under deep ether anesthesia. A volume of 100 ml urine was removed by aspiration and the urine TNFa concentration was evaluated by ELISA. At 4 weeks after tumor implantation, four mice administrated with Ad-hUPII-TNF and five with Ad-hUPII-GFP were killed and their bladders were removed. The respective bladders and body weights were measured to determine bladder (mg)-to-body (g) weight ratios and the bladder volumes were determined. The national and institutional guidelines were followed in the whole process.
Results
Expression of UPII mRNA in different cell lines
To confirm the specific expression pattern of UPII in urothelial cells, a pair of primers was designed according to the cDNA sequence of UPII and RT-PCR was performed. The B322-bp PCR products were detected in all bladder cancer cell lines BIU-87 and UPII showed a high level of expression in bladder cancer cell line BIU-87, but a low level or no expression in the bladder cancer cell line EJ or other tissue cell lines (Fig 2) .
Sequence of the UPII promoter
A 2542-bp UPII promoter was generated by PCR and cloned into a vector for sequencing. The sequence of PCR product is identical to the 5 0 -flanking sequence of human UPII gene the in human genome (see Fig 3) . The sequence between À142 and À139 matches the consensus TATA box sequence for mammalian RNA polymerase II promoters. Alignment analysis of the sequence found approximately 88% homology between the hUPII (À134 to À74) and mouse UPII promoter region (À77 to À1).
Tissue specificity of the cloned hUPII promoter
To test the tissue specificity of this fragment, two constructs were generated: the 2542-bp hUPII promoter was either cloned upstream an enhanced GFP gene (phUPII-EGFP), or a Luc gene (phUPII-Luc).
Firstly, phUPII-EGFP was transiently transfected into a human bladder cell line BIU-87, renal carcinoma (GRC-1), and human endothelial (EC) cell lines. The number of cells expressing GFP was determined by flow cytometric analysis. The percentage of GFP-positive cells in BIU-87 cell line, EC cell line, and GRC-1 cell line was 10.1, 1.8, and 0% respectively (Fig 4) .
Secondly, various cell lines, including BIU-87, EJ, GRC-1, Hs27, EC, and A549, were cotransfected with phUPII-Luc and an internal control plasmid, pCMVb-gal (with the CMV promoter driving the b-galactosidase gene) (Fig 5) . In BIU-87 cells, Luc activity is the highest, compared to bladder cancer cell line EJ and other nonurothelium cells. The difference ranged from 2.2-to 10-folds. These results indicate that the DNA fragment of 2542 bp contains a promoter that is highly active in urothelium cells and directs the tissue-specific and regulated expression of the UPII gene in urothelium cells.
Identification of a transcriptional regulatory element for the UPII gene
The 2542-bp 5 0 -flanking region was sequenced by fluorescent dye terminator labeled by AmpliTaq DNA polymerase. Computer analysis of the sequence found a number of matches to consensus-binding sites for various transcription factors (Fig 5) .
To investigate the transcriptional control of this promoter, various 5 0 and 3 0 deletions were created (Fig 1) . The deletion of the sequence between À2545 and À1608 (hUPII) resulted in a significant reduction in Luc activity in BIU-87 cells but not in nonurothelium cells. All cell lines transfected with constructs hUPII-2 (deletion from À2545 to À1034), hUPII-5 (deletion from À2545 to À328) demonstrated the similar Luc activity. The Luc activity was barely detected in constructs hUPII-3 (deletion from À1672 to À4) and hUPII-4 (deletion from À328 to À4). These results indicate that the sequence from À2545 to À1608 is important to tissue specificity of the promoter and the sequence from À328 to À4 is the core sequence of the promoter.
Tissue-specific expression of TNFa driven by hUPII promoter
The key point in gene targeting therapy is to use a tissuespecific regulator to drive therapeutic gene expression in target cells. To introduce TNFa into bladder tumor cells, two replication-deficient adenoviruses (Ad) were generated as described in Materials and methods. Under the control of the hUPII promoter, Ad-hUPII-TNF is used to express TNFa gene, whereas Ad-hUPII-GFP is used to express GFP gene as a control. To investigate whether the Ad viruses described above preferentially and efficiently give the expression of genes downstream hUPII promoter in bladder cancer cells, ELISA was performed. The productivity of TNFa was evaluated in the culture medium of bladder tumor cell lines (BIU-87), lung cell line (A549) after 48-hour infection of the above virus at progressively increased MOIs. A significantly high level of TNFa was detected in the medium of Ad-hUPII-TNFinfected BIU-87 bladder cancer cell line, as compared to all of the other cell lines either transfected by Ad-hUPII-TNF or Ad-hUPII-GFP. As shown in Figure 6a , the TNFa expression in BIU-87 was both MOI-and time-dependent. For example, in the culture medium from Ad-hUPII-TNF-infected BIU-87 cells, the concentration of TNFa peaked at 48 hours and MOI 50, and then began to decrease after 60 hours. Thus, the hUPIIengineered Ad preferentially express TNFa in bladder cancer cells, suggesting that hUPII promoter retains its intrinsic bladder cancer-specific function and drives the TNFa gene expression restricted in BIU-87 bladder cells.
Antitumor efficacy of Ad-hUPII-TNF in vitro
To test the antitumor effect of Ad-hUPII-TNF, cytolytic specificity was further examined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. After BIU-87 cells were infected with either Ad-hUPII-TNF or Ad-hUPII-GFP, cell viability was determined at various MOIs by MTT assay. The significant toxicity was observed in Ad-hUPII-TNF transfected bladder cancer UPII signals detected in semiquantitative PCR. One-twentieth of the cDNA derived from 3 mg of total RNA was used as a template for 30 cycles of PCR. Bands in 2% agarose gels loaded with 5 ml of the respective PCR using UPII and b-actin primers are demonstrated. A B322-bp UPII PCR product was only observed in human bladder cancer cell line BIU-87, whereas in the other human cell lines and even another human bladder cell line EJ, no or extremely low UPII mRNA was detected. The lower panel showed RT-PCR analysis of the same set of RNA samples for b-actin, as internal control (541 bp).
(1) Marker, (2) A549, (3) GRC-1, (4) Hs27, (5) EC, (6) BIU-87, (7) EJ.
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cell (BIU-87) (Fig 6c) , and cell viability decreased steeply with increased MOI. In contrast, the viability of AdhUPII-GFP-infected BIU-87 cells was almost 100% in this experiment.
To further investigate the accuracy of the above experiment, a TNFa-sensitive cell line L929 was incubated with the cell culture media from BIU-87 cells infected with Ad-hUPII-TNF or Ad-hUPII-GFP at various MOI. The Figure 3 The 2542-bp 5 0 -flanking region was sequenced by fluorescent dye terminator labeling using AmpliTaq DNA polymerase. Computer analysis of the sequence found a number of matches to consensus-binding sites for various transcription factors. In particular, the sequence between -142 and -139 matches the consensus TATA box sequence for mammalian RNA polymerase II promoters (framed). Alignment analysis of the sequence found approximately 88% homology between the hUPII (underlined) and the mouse UPII promoter region. An asterisk marks the first extron of ATG start codon.
viability of L929 was examined by MTT assay. As shown in Figure 6d , the Ad-hUPII-TNF-infected media killed L929 cells in an MOI-dependent manner, which is consistent with the productivity of TNFa. However, culture media from Ad-hUPII-GFP-infected BIU-87 cells and Ad-hUPII-TNF-or Ad-hUPII-GFP-infected A549 cells had little effect on L929 cells. These data suggest that the bioactivity of TNFa generated by infected bladder cancer cell line BIU-87 is effective enough to kill the cancer cells.
Antitumor effect on orthotopic human bladder tumors
To determine the in vivo antitumor effect of Ad-hUPII-TNF, the orthotopic bladder cancer xenograft tumor model was employed. The intravesical instillation of AdhUPII-TNF (10 7 PFU) or the control virus (Ad-hUPII-GFP) was performed on the nude mice orthotopically implanted with BIU-87 bladder cancer cells. After 48 hours, the amount of TNFa in the urine of Ad-hUPII-TNF administrated mice was 1.7-fold higher than the control virus-treated mice with ELISA analysis (Po.05) (Fig 7a) . After 4 weeks, the mean tumor bladder weight and volume of these mice were significantly reduced (Po.05) compared with the control group (Fig 7b, c) .
Discussion
Although several modalities of surgical resection, chemotherapy, and radiotherapy to treat bladder cancer are currently under investigation, none has demonstrated a decrease in recurrent rate. 20, 31 In the past few years, several new approaches, including gene therapy, have been proposed. Successful gene therapy requires not only the identification of an appropriate therapeutic gene for the treatment of the disease but also a delivery system by which the gene can be delivered efficiently and accurately to the desired target cell types. 22 One such approach is to use a tissue-specific promoter to drive the expression of the therapeutic genes so that the gene is expressed only in the specific target cell types and systemic toxicity is minimized. 23 UPII, a bladder tissue-specific gene, has been studied extensively in humans, mice, and cows. 24, 25 Previously, a 3.6-kb flanking sequence of the mouse UPII gene was shown to confer tissue specificity to reporter gene expression in the urothelium of transgenic mice. 18 In the current study, we cloned a 2542-bp DNA fragment that flanks 5 0 of the UPII gene from human peripheral blood. Sequence alignment indicated an 88% similarity in the promoter region between the hUPII promoter and the mouse UPII promoter. This region in the hUPII promoter contains motifs that are typically found in the promoter region.
Understanding the unique mechanism of the promoter's transcriptional control may prove to be beneficial in developing target-specific expression vectors for bladder cancer gene therapy. In this study, we characterized the role of the human UPII promoter in human bladder cancer cells. Our results are the first to demonstrate that the 2542-bp 5 0 flanking sequence of human UPII can drive TGF gene expression in bladder cancer cells both in vitro and in vivo to inhibit the bladder cancer cell growth. Compared with the mouse UPII promoter, the human UPII promoter has higher activity and better tissue specificity in human cell lines (unpublished). The deletion analysis further revealed that (i) 973-bp of the 5 0 flank of the hUPII promoter can decide the activity and tissue specificity of the hUPII. The tissue-specific regulatory element was located in the 973-bp region of the 5 0 flank (from À2545 to À1608) of the hUPII promoter. (ii) Even 325 bp of the hUPII promoter was sufficient to exhibit basic promoter activity. The core promoter was contained in the 325-bp region of the 3 0 flank (from À328 to À4). These features of the UPII promoter are fundamental to the development of a target-specific vector for gene therapy.
Recently, Zhang co-workers 26 described the DNA fragment upstream of the human UPII gene using walking PCR. The length of amplification is 2239 bp, with the TATA box located at À81 to À87. In the current study, we used an easier method and amplified a 2542-bp 5 0 flanking region of the human UPII gene. Computer analysis of the sequence found that the sequence between À142 and À139 matched the consensus TATA box sequence for mammalian RNA polymerase II promoters. Since Zhang and co-workers did not publish the cloned sequence of the hUPII promoter, the discrepancy in the location of the TATA box is not clear. Furthermore, we described the transcriptional control of the hUPII promoter.
UPII are bladder-derived cell specific, so the hUPII promoter is active in both the normal bladder tissues and Figure 7 Efficacy of Ad-hUPII-TNF in the treatment of orthotopic human bladder tumor model. (a) At 48 hours after tumor implantation, three mice injected with Ad-hUPII-TNF and three with Ad-hUPII-GFP were killed under deep ether anesthesia. A total of 100 ml of urine was aspirated. TNFa in the urine was analyzed by ELISA. The concentration of TNFa in mice treated with Ad-hUPII-TNF was 1.7-fold that of the mice treated with Ad-hUPII-GFP. (b) At 4 weeks after tumor implantation, four mice injected with Ad-hUPII-TNF and five injected with Ad-hUPII-GFP were killed and their bladders were excised. The respective bladders and the bodies were weighed to determine the bladder weight (mg)-to-body (g) ratios. The mean tumor bladder weight in mice treated with Ad-hUPII-TNF was significantly lower than that of mice treated with Ad-hUPII-GFP. (c) The bladder volumes were measured on day 28 after intravesical treatment. The mean tumor bladder volume in mice treated with Ad-hUPII-TNF was significantly lower than that of mice treated with Ad-hUPII-GFP.
cancer cells. TNFa is a naturally occurring product known to stimulate natural and lymphokine-activated killer cells and to modulate granulocytes and B-cell function. TNFa is an antitumor agent that has been shown to be cytotoxic and cytostatic in vitro, and it appears to inhibit cell proliferation during the G2 phase of the cell cycle. 27 It has been suggested that TNFa specifically affects tumors but not normal tissue. 28 The antitumor effect of TNFa has now been established in various animal model systems. 29, 30 Bacillus CalmetteGuerin (BCG), an intravesical agent, appears to decrease the recurrence rate of superficial bladder cancer. BCG has been shown to induce TNFa, which may be a mechanism of action of BCG antitumor activity in superficial bladder cancer. So, in our animal study, normal bladder cells could produce TNFa, but TNFa has little or no effect on normal bladder cells and only affects bladder cancer cells.
In vitro, the expression of the adenovirus Ad-hUPII-TNF was confirmed in the infected BIU-87 cells with ELISA and anti-TNFa antibodies. The level of TNFa in Ad-hUPII-TNF-infected BIU-87 cells was significantly higher than in Ad-hUPII-GFP-infected BIU-87 cells and Ad-hUPII-TNF-infected A549 cells. These results guaranteed that the hUPII promoter still retains the tissuespecificity in an adenovirus vector. MTT analysis revealed that the viability of Ad-hUPII-TNF-infected BIU-87 cells was about the same as for BIU-87 cells treated with exogenous recombinant TNFa protein. Furthermore, the treatment of BIU-87 cells with the conditioned medium obtained from infected cells resulted in an apparent inhibition of L929 cells. This result confirmed that the adenovirus Ad-hUPII-TNF has a high activity to produce enough TNFa and induce cell death. Hence, adenovirus vectors that contain the hUPII promoter may be useful for gene therapy against bladder cancer.
It is known that the progression of any tumor cell is influenced by both the genetic composition of the cell and the surrounding microenvironment. The activity of microenvironment factors such as autocrine, paracrine, and endocrine factor(s) contributed by either neighboring normal cells, the stromal component, or circulation often can modulate phenotypic changes in tumor cells. An in vivo orthotopic tumor model can simulate the progression of human tumor cells. 14 We used orthotopic xenograft model, which is superior to subcutaneous transplantation models in evaluating gene transfer methods and assessing the efficiency of gene transfer in vivo. In the presence of the TNFa gene adenovirus Ad-hUPII-TNF, we observed a significant suppression of the growth of bladder tumors with respect to tumor volume and weight. Meanwhile, the intravesical instillation method is very close to clinical treatment in bladder cancer.
In conclusion, our study indicates that the promoter of the hUPII gene can confer preferential expression of genes in the bladder urothelium. Further, we determined the transcriptional control of the hUPII promoter to define the tissue-specific regulatory element (from À2545 to À1608) and core regulatory element (from À328 to À4). An adenoviral vector containing TNFa driven by the hUPII promoter showed high antitumor efficacy in vitro and in vivo. Our results may yield a new approach to therapy for bladder cancer and provide some information on the molecular regulation of urothelial growth, differentiation, and disorders.
